Encorafenib,Cetuximab,Binimetinib
Pfizer,Eli Lilly,Array Biopharma
['beacon']
translational data from the beacon trial: kras, nras, map2k1 mutations and met amplification as key mechanisms of acquired resistance, leading to reactivation of the mapk pathway. most of these alterations were subclonal-&gt; limitation for resistance overcoming strategies #esmo2022
28. MD. PhD student. Medical Oncology trainee at Ramón y Cajal University Hospital (Madrid). ES ????| EN ????| FR ????| ZH ????| ???? ??Avid traveller! ????